Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey.
Laryngoscope. 2014 Aug;124(8):1877-81. doi: 10.1002/lary.24618. Epub 2014 Mar 11.
OBJECTIVES/HYPOTHESIS: Laryngeal chondrosarcoma (LC) is a rare entity, reportedly comprising less than 1% of all laryngeal tumors. Consequently, the incidence and survival of patients with this slow-growing tumor has been difficult to study. Our objective was to evaluate incidence, organized by patient demographics, as well as long-term survival trends of this malignancy using a population-based database.
Retrospective analysis of the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry.
The SEER database was searched for patients diagnosed with LC between 1973 and 2010. Data analyzed included patient demographics, incidence, treatment modality, and survival.
One-hundred and forty-three cases were identified, representing 0.2% of all laryngeal tumors. Median age at diagnosis was 61.7 years. Men and women constituted 76.2% and 23.8% of patients, respectively. Tumors were locally invasive with 37.7% T4 disease and infrequent regional and distant metastases. The 1-year, 5-year, and 10-year disease-specific survival for LC was 96.5%, 88.6%, and 84.8%, respectively, compared to 88.3%, 68.2%, and 59.3%, respectively for patients with all other laryngeal tumors (P values < 0.01). Relative survival was 94.9% at 1 year, 88.5% at 5 years, and 88.4% at 10 years.
This analysis represents the largest LC study sample to date, allowing for evaluation of incidence and long-term survival. LC occurs infrequently, is locally invasive, but only rarely metastasizes. Prognosis for LC is significantly better than for other laryngeal malignancies.
目的/假设：喉软骨肉瘤（LC）是一种罕见的实体瘤，据报道其占所有喉肿瘤的比例不到 1%。因此，这种生长缓慢的肿瘤的发病率和患者生存率很难研究。我们的目的是使用基于人群的数据库评估这种恶性肿瘤的发病率，并根据患者的人口统计学进行组织，以及长期生存趋势。
对美国国家癌症研究所的监测、流行病学和最终结果（SEER）登记处进行回顾性分析。
在 SEER 数据库中搜索 1973 年至 2010 年间诊断为 LC 的患者。分析的数据包括患者的人口统计学、发病率、治疗方式和生存情况。
共确定了 143 例病例，占所有喉肿瘤的 0.2%。诊断时的中位年龄为 61.7 岁。男性和女性分别占患者的 76.2%和 23.8%。肿瘤具有局部侵袭性，37.7%的患者 T4 期疾病和不常见的区域和远处转移。LC 的 1 年、5 年和 10 年疾病特异性生存率分别为 96.5%、88.6%和 84.8%，而所有其他喉部肿瘤患者的生存率分别为 88.3%、68.2%和 59.3%（P 值<0.01）。相对生存率为 1 年时为 94.9%，5 年时为 88.5%，10 年时为 88.4%。
这是迄今为止最大的 LC 研究样本，可用于评估发病率和长期生存率。LC 发病率较低，具有局部侵袭性，但很少发生转移。LC 的预后明显优于其他喉部恶性肿瘤。
